Table 3. Trial characteristics by phase.

Trial phase	Trial type	n of trials	Randomized	Double blinded	Placebo controlled	All three
Phase I trials	COVID related	8	2 (25%)	2 (25%)	2 (25%)	2 (25%)
	Non-COVID related mean of three sets	10.67	3 (28.1%)	1.33 (12.5%)	0 (0%)	0 (0%)
Phase I/II trials	COVID related	19	13 (68.4%)	6 (31.6%)	9 (47.4%)	5 (26.3%)
	Non-COVID related mean of three sets	10.33	7.67 (74.2%)	2.33 (22.6%)	6 (58.1%)	2.33 (22.6%)
Phase II trials	COVID related	19	16 (84.2%)	9 (47.4%)	12 (63.2%)	9 (47.4%)
	Non-COVID related mean of three sets	7.33	4.33 (59.1%)	3 (40.9%)	2.33 (31.8%)	2.33 (31.8%)